4175.TWO · MEDFIRST
Taiwan · RS rating 43 · As of 2026-10-08
| Price | 51.00 TWD |
|---|---|
| 1-day change | +0.6% |
| RS rating (overall / 1M / 3M / 12M) | 43 / 39 / 62 / 36 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 38 / 25 / 46 |
| Industry group (rank) | Medical-Biomed/Biotech (53) |
| EPS growth Q/Q | +221.1% |
| Sales growth Q/Q | +10.1% |
| Distance from 52-week high | +15.7% |
| Market cap (USD) | $67.2M |